Sign in or Register   Sign in or Register
  |  

Mouse Anti-MYH9 Recombinant Antibody (1H6) (CBMAB-A5720-LY)

The product is antibody recognizes MYH9. The antibody 1H6 immunoassay techniques such as: WB, ELISA.
See all MYH9 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1H6
Antibody Isotype
IgG2b, κ
Application
WB, ELISA

Basic Information

Immunogen
MYH9 (NP_002464.1, 1871 a.a. ~ 1960 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Myosin Heavy Chain 9
Introduction
This gene encodes a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain. The protein is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in MYH9 are the cause of non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness. [provided by RefSeq]
Entrez Gene ID
4627
UniProt ID
P35579
Alternative Names
DFNA17; EPSTS; FTNS; MGC104539; MHA; NMHC-II-A; NMMHCA
Function
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis (By similarity).

Promotes cell motility in conjunction with S100A4 (PubMed:16707441).

During cell spreading, plays an important role in cytoskeleton reorganization, focal contact formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10 (PubMed:20052411).
Biological Process
Actin cytoskeleton reorganization Source: UniProtKB
Actin filament-based movement Source: UniProtKB
Actomyosin structure organization Source: UniProtKB
Angiogenesis Source: UniProtKB
Blood vessel endothelial cell migration Source: UniProtKB
Cortical granule exocytosis Source: UniProtKB
Cytokinetic process Source: UniProtKB
Establishment of meiotic spindle localization Source: Ensembl
Establishment of T cell polarity Source: Ensembl
Integrin-mediated signaling pathway Source: UniProtKB
In utero embryonic development Source: Ensembl
Leukocyte migration Source: UniProtKB
Lysosome localization Source: UniProtKB
Meiotic spindle organization Source: Ensembl
Membrane protein ectodomain proteolysis Source: UniProtKB
Monocyte differentiation Source: UniProtKB
Myoblast fusion Source: Ensembl
Negative regulation of actin filament severing Source: UniProtKB
Phagocytosis, engulfment Source: UniProtKB
Plasma membrane repair Source: UniProtKB
Platelet aggregation Source: UniProtKB
Platelet formation Source: UniProtKB
Positive regulation of protein processing in phagocytic vesicle Source: UniProtKB
Protein transport Source: UniProtKB
Regulated exocytosis Source: UniProtKB
Regulation of cell shape Source: UniProtKB
Regulation of plasma membrane repair Source: UniProtKB
Uropod organization Source: Ensembl
Cellular Location
Cytoskeleton
Other locations
cell cortex
Cortical granule
Note: Colocalizes with actin filaments at lamellipodia margins and at the leading edge of migrating cells (PubMed:20052411). In retinal pigment epithelial cells, predominantly localized to stress fiber-like structures with some localization to cytoplasmic puncta (PubMed:27331610).
Involvement in disease
Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss (MATINS):
An autosomal dominant disorder characterized by thrombocytopenia, giant platelets and Dohle body-like inclusions in peripheral blood leukocytes with variable ultrastructural appearance. Some affected individuals lack leukocyte inclusion bodies on classic staining of peripheral blood smears. Alport syndrome-like features of nephritis, hearing loss, and eye abnormalities are present in some patients.
Deafness, autosomal dominant, 17 (DFNA17):
A form of deafness characterized by progressive high frequency hearing impairment and cochleosaccular degeneration.
Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.
Genetic variations in MYH9 are associated with non-diabetic end stage renal disease (ESRD).
PTM
ISGylated.
Ubiquitination.

Poppelaars, F., Eskandari, S. K., Damman, J., Seelen, M. A., Faria, B., & da Costa, M. G. (2023). A non-muscle myosin heavy chain 9 genetic variant is associated with graft failure following kidney transplantation. Kidney Research and Clinical Practice, 42(3), 389.

Han, X., Clark, J. J., Sharma, P., Bentley, E. G., Kipar, A., Alsayer, M., ... & Zhao, Q. (2023). Amino acids 1811–1960 of myosin heavy chain 9 is involved in murine gammaherpesvirus 68 infection. Virology, 587, 109849.

Zhang, H., Liu, S., Tang, L., Ge, J., & Lu, X. (2021). Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9). Bioengineered, 12(1), 162-171.

Wang, S., Li, S., Li, Y., Jiang, Q., Li, X., Wang, Y., ... & Chen, Y. G. (2021). Non-muscle myosin heavy chain 9 maintains intestinal homeostasis by preventing epithelium necroptosis and colitis adenoma formation. Stem Cell Reports, 16(5), 1290-1301.

Thurlapati, A., Guntupalli, S., Mansour, R., & Mansour, R. P. (2021). Myosin heavy chain 9 (MYH9)-related congenital macrothrombocytopenia. Cureus, 13(8).

Shao, L., Zhao, J., & Tang, Q. (2021). Non-muscle myosin heavy chain 9 is a critical factor for infectious pancreatic necrosis virus cellular entry. Aquaculture, 533, 736138.

Zhou, W., Huo, J., Yang, Y., Zhang, X., Li, S., Zhao, C., ... & Wang, C. (2020). Aminated fullerene abrogates cancer cell migration by directly targeting myosin heavy chain 9. ACS Applied Materials & Interfaces, 12(51), 56862-56873.

Asensio-Juárez, G., Llorente-González, C., & Vicente-Manzanares, M. (2020). Linking the landscape of MYH9-related diseases to the molecular mechanisms that control non-muscle myosin II-A function in cells. Cells, 9(6), 1458.

Wang, Y., Liu, S., Zhang, Y., & Yang, J. (2019). Myosin heavy chain 9: oncogene or tumor suppressor gene?. Medical science monitor: international medical journal of experimental and clinical research, 25, 888.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MYH9 Recombinant Antibody (1H6)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare